Phospho-SNCA (Tyr133) Antibody

What is Phospho-SNCA (Tyr133) and why is it significant in neurodegenerative disease research?

Phospho-SNCA (Tyr133) refers to alpha-synuclein (SNCA) that is phosphorylated at the tyrosine 133 residue. Alpha-synuclein is a neuronal protein involved in synaptic vesicle trafficking and neurotransmitter release, and is the main component of Lewy bodies found in Parkinson's disease .

The significance of Tyr133 phosphorylation stems from evidence suggesting that tyrosine phosphorylation may have opposing effects to serine phosphorylation (particularly at Ser129), potentially offering neuroprotective properties . While approximately 90% of alpha-synuclein in Lewy bodies is phosphorylated at Ser129, tyrosine phosphorylation sites including Tyr133 appear to influence alpha-synuclein's neurotoxicity and aggregation properties differently .

Understanding Tyr133 phosphorylation provides critical insights into:

• The mechanisms governing alpha-synuclein's physiological functions

• The pathological transitions leading to neurodegeneration

• Potential therapeutic targets for modulating alpha-synuclein aggregation

How does phosphorylation at Tyr133 differ from phosphorylation at Ser129?

The two phosphorylation sites differ in several key aspects:

Research indicates that increasing tyrosine phosphorylation through expression of Src tyrosine kinase (Shark) ameliorated alpha-synuclein neurotoxicity in Drosophila models . These opposing effects make Tyr133 phosphorylation particularly interesting for therapeutic research.

What are the typical applications for Phospho-SNCA (Tyr133) antibodies in neurological research?

Phospho-SNCA (Tyr133) antibodies serve multiple crucial functions in neurological research:

• Detection and quantification: Specific measurement of Tyr133-phosphorylated alpha-synuclein in various biological samples .

• Cellular assays: Cell-based ELISA kits enable studying how different experimental conditions affect Tyr133 phosphorylation levels in cultured cells .

• Immunohistochemistry and immunofluorescence: Visualization of Tyr133-phosphorylated alpha-synuclein distribution in brain tissue sections .

• Western blotting: Detection and semi-quantitative analysis of Phospho-SNCA (Tyr133) in protein samples at typical dilutions of 1:500-1:2000 .

• Mechanistic studies: Investigation of signaling pathways and mechanisms regulating Tyr133 phosphorylation when used with kinase inhibitors or genetic manipulations .

• Biomarker development: Contributing to efforts identifying potential biomarkers for Parkinson's disease diagnosis or monitoring disease progression .

These applications collectively advance our understanding of alpha-synuclein biology in both normal physiology and pathological states.

How do post-translational modifications near Tyr133 affect antibody detection?

The presence of multiple post-translational modifications (PTMs) near Tyr133 can significantly impact antibody detection and experimental outcomes. This represents a critical consideration for experimental design:

• Epitope masking effects: Research has demonstrated that "the co-occurrence of multiple pathology-associated C-terminal post-translational modifications (e.g., phosphorylation at Tyrosine 125 or truncation at residue 133 or 135) differentially influences the detection of pS129-aSyn species by pS129-aSyn antibodies" . Similar interference likely affects Tyr133 antibody detection.

• Truncation interference: C-terminal truncations around residue 133, which are common in pathological alpha-synuclein, can directly eliminate the Tyr133 site or alter local protein conformation affecting antibody recognition .

• Antibody specificity variations: The search for highly specific antibodies remains challenging. As noted in one study: "We identified two antibodies that are insensitive to pS129 neighboring PTMs. Although most pS129 antibodies showed good performance in detecting aSyn aggregates... they also showed cross-reactivity towards other proteins" . Similar issues likely apply to Tyr133 antibodies.

• Methodological solutions: To address these challenges, researchers should:

  • Use multiple antibodies targeting different epitopes

  • Include appropriate controls (dephosphorylated samples, Y133F mutants)

  • Validate findings with complementary techniques like mass spectrometry

  • Consider using antibodies specifically characterized as insensitive to neighboring PTMs

Understanding these limitations is essential for accurate interpretation of experimental results when using Phospho-SNCA (Tyr133) antibodies.

What methodological approaches effectively validate Phospho-SNCA (Tyr133) antibody specificity?

Validating antibody specificity requires a multi-faceted approach. The following methodologies can effectively establish Phospho-SNCA (Tyr133) antibody specificity:

• Phosphatase treatment controls:

  • Treatment with phosphatases should abolish antibody reactivity if truly phospho-specific

  • Example: "Pretreatment of the homogenate from the brains of flies expressing wild-type α-synuclein with phosphatase to remove phosphate groups abolished immunoreactivity"

• Genetic mutation controls:

  • Testing against Y133F mutants (where tyrosine is replaced with phenylalanine)

  • As demonstrated in studies of similar sites: "Specificity of the antibody was supported by lack of immunoreactivity following substituting Tyr125 to phenylalanine"

• Western blotting validation:

  • The Anti-Synuclein-α (Phospho-Tyr133) Antibody specificity can be tested on Western Blots

  • Testing against recombinant proteins with and without in vitro phosphorylation

• Two-dimensional gel electrophoresis:

  • Separates proteins based on both molecular weight and isoelectric point

  • Helps distinguish different phosphorylated species of alpha-synuclein

• Kinase overexpression:

  • Increased phosphorylation through kinase overexpression should enhance antibody signal

  • "Overexpression of shark increased phosphorylation at Tyr125 on α-syn WT" , and similar approaches could validate Tyr133 antibodies

• Cross-reactivity assessment:

  • Testing against alpha-synuclein knockout samples to identify non-specific binding

  • Many antibodies "detected non-specific low and high molecular weight bands in aSyn knock-out samples that could be easily mistaken for monomeric or high molecular weight aSyn species"

Comprehensive validation using multiple approaches provides the strongest evidence for antibody specificity, which is essential for reliable research outcomes.

How can researchers accurately quantify the proportion of alpha-synuclein phosphorylated at Tyr133?

Accurate quantification of Tyr133-phosphorylated alpha-synuclein requires specialized techniques and careful consideration of several factors:

• Cell-Based ELISA Approaches:
  Multiple normalization methods are recommended for Cell-Based ELISA kits:

  • Anti-GAPDH antibody serves as an internal positive control

  • Crystal Violet whole-cell staining determines cell density

  • Anti-alpha Synuclein antibody provides normalization for total alpha-synuclein levels

• Two-dimensional gel electrophoresis with Western blotting:

  • Can separate different post-translationally modified forms

  • In Drosophila models, this approach revealed "approximately 30% of total α-synuclein was phosphorylated at Tyr125"

  • Similar methodology can be applied to Tyr133 quantification

• Critical technical considerations:

  • Post-mortem dephosphorylation: "The reactivity of α-synuclein to anti-PY125 decreased with increasing intervals of incubation, consistent with postmortem dephosphorylation"

  • Phosphatase inhibition: Samples must be prepared with appropriate phosphatase inhibitor cocktails

  • Appropriate controls: Include phospho-null mutants (Y133F) as negative controls

  • Normalization strategy: Normalize to total alpha-synuclein rather than total protein

• Assay sensitivity and specificity:

  • ELISA kits typically offer a dynamic range of >5000 cells

  • Recommended antibody dilutions for Western blot applications range from 1:500-1:2000

  • For ELISA applications, optimal starting concentration is typically 1 μg/mL

• Standardization across experiments:

  • Use consistent sample collection and processing procedures

  • Include standard curves with known quantities of phosphorylated recombinant protein

This multi-faceted approach with appropriate controls provides the most reliable quantification of Tyr133 phosphorylation levels.

How does phosphorylation at Tyr133 affect alpha-synuclein aggregation compared to other sites?

The differential effects of phosphorylation sites on alpha-synuclein aggregation properties are critical for understanding disease mechanisms:

• Contrasting effects of tyrosine versus serine phosphorylation:

  • Tyrosine phosphorylation (including at Y133) appears to have protective effects against aggregation

  • "Phosphorylation at Ser-129 promoted insoluble fibril formation" in vitro

  • Research suggests that "tyrosine and serine phosphorylation of α-synuclein have opposing effects"

• Mechanistic basis for these differences:

  • Charge effects: Phosphorylation introduces negative charges that differently affect protein folding depending on local environment

  • Conformational changes: Different phosphorylation sites induce distinct structural changes

  • Protein interactions: Sites may mediate interactions with different binding partners that modify aggregation propensity

• Experimental evidence:

  • In Drosophila models, "Coexpression of shark significantly rescued the neurotoxicity of both α-syn WT and α-syn S129D" by increasing tyrosine phosphorylation

  • The ability of tyrosine phosphorylation to counteract the effects of S129D (a Ser129 phosphomimetic) suggests opposing functional effects

• Quantitative significance:

  • Approximately 30% of total α-synuclein was phosphorylated at tyrosine residues in Drosophila models

  • This substantial proportion supports the physiological relevance of tyrosine phosphorylation in modulating alpha-synuclein properties

Understanding these differential effects may provide valuable insights for therapeutic strategies aimed at reducing pathological alpha-synuclein aggregation in neurodegenerative diseases.

What challenges exist in studying Tyr133 phosphorylation in post-mortem human brain samples?

Post-mortem human brain studies of Tyr133 phosphorylation face several significant methodological challenges:

• Rapid post-mortem dephosphorylation:

  • "The reactivity of α-synuclein to anti-PY125 decreased with increasing intervals of incubation, consistent with postmortem dephosphorylation"

  • Similar rapid dephosphorylation likely affects Tyr133, potentially leading to false negatives

• Variable tissue preservation conditions:

  • Post-mortem interval variations between samples introduce inconsistency

  • Phosphorylation status highly dependent on tissue processing speed and conditions

• Antibody specificity limitations:

  • Studies show many antibodies "detected non-specific low and high molecular weight bands in aSyn knock-out samples that could be easily mistaken for monomeric or high molecular weight aSyn species"

  • Cross-reactivity with other phosphorylated proteins complicates interpretation

• Multiple PTM interference:

  • "The co-occurrence of multiple pathology-associated C-terminal post-translational modifications (e.g., phosphorylation at Tyrosine 125 or truncation at residue 133 or 135) differentially influences the detection"

  • Complex PTM patterns in disease tissue further complicate reliable detection

• Tissue heterogeneity issues:

  • Disease progression variability between patients

  • Cell-type specific differences in phosphorylation patterns

• Technical solutions:

  • Immediate phosphatase inhibition during tissue processing

  • Use of multiple antibodies against different epitopes containing phosphorylated Tyr133

  • Complementary mass spectrometry approaches for site-specific identification

  • Implementation of proximity ligation assays for increased specificity

These challenges necessitate careful experimental design and appropriate controls when studying Tyr133 phosphorylation in human brain tissue.

How can researchers distinguish physiological from pathological roles of Tyr133 phosphorylation?

Distinguishing physiological from pathological roles of Tyr133 phosphorylation requires multifaceted experimental approaches:

• Quantitative comparison across disease states:

  • Analyzing Tyr133 phosphorylation levels in healthy controls versus Parkinson's disease patients

  • Recent research shows "human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma"

  • ROC curve analysis indicated that "α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects"

• Functional studies in model systems:

  • Expression of phospho-mimetic (Y133D/E) versus phospho-null (Y133F) mutants

  • Evaluating effects on normal synaptic functions versus pathological aggregation

  • Studies have shown "coexpression of shark significantly rescued the neurotoxicity of both α-syn WT and α-syn S129D" by increasing tyrosine phosphorylation

• Kinase/phosphatase regulation:

  • Analysis of enzymes controlling phosphorylation status

  • In PD patients, phosphorylation rates "were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn)"

• Structural and biochemical analysis:

  • Examining how Tyr133 phosphorylation affects alpha-synuclein conformation

  • Investigating differences in protein-protein interactions mediated by this modification

• Integration with other PTMs:

  • Analyzing how Tyr133 phosphorylation interacts with other modifications

  • Studies show no apparent influence of Ser129 phosphorylation on phosphorylation of Tyr125: "Similar levels of phospho-Tyr125 were present in flies expressing α-syn WT, α-syn S129A, and α-syn S129D"

This integrated approach enables researchers to distinguish normal functions from pathological roles, providing insights for targeted therapeutic development.

What are the most promising methods for developing Tyr133 phosphorylation as a biomarker?

Development of Tyr133 phosphorylation as a biomarker requires robust methodologies that overcome technical challenges while providing clinically relevant information:

• Plasma-based assays:

  • Recent research demonstrated that "human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma"

  • "Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects"

  • These findings suggest similar approaches could be developed specifically for Tyr133 phosphorylation

• ELISA-based quantification systems:

  • Cell-Based ELISA kits allow for detection of phosphorylated alpha-synuclein and effects of stimulation conditions

  • Multiple normalization methods enhance reliability:

    • Anti-GAPDH antibody as internal control

    • Crystal Violet whole-cell staining for cell density normalization

    • Anti-alpha Synuclein antibody for total protein normalization

• Correlation with disease parameters:

  • Alpha-synuclein phosphorylation rates have been shown to be "positively correlated with Hoehn and Yahr staging"

  • This suggests phosphorylation biomarkers may have value for disease staging and progression monitoring

• Enzyme activity correlations:

  • Phosphorylation rates correlate with activities of relevant enzymes:

    • Positive correlation with polo-like kinase 2 (PLK2) levels

    • Negative correlation with protein phosphatase 2A (PP2A) levels

    • Negative correlation with glucocerebrosidase (GCase) activity

• Technical specifications for assay development:

  • ELISA kits typically offer dynamic range of >5000 cells

  • For Western blot applications, antibody dilutions range from 1:500-1:2000

  • For ELISA applications, optimal starting concentration is typically 1 μg/mL

These approaches collectively provide promising avenues for developing Tyr133 phosphorylation as a clinically useful biomarker for synucleinopathies.

What controls are essential when using Phospho-SNCA (Tyr133) antibodies?

Proper controls are critical for ensuring reliable and interpretable results when using Phospho-SNCA (Tyr133) antibodies:

• Phosphatase treatment controls:

  • Treating samples with phosphatases should abolish antibody reactivity

  • "Pretreatment of the homogenate from the brains of flies expressing wild-type α-synuclein with phosphatase to remove phosphate groups also abolished immunoreactivity"

• Genetic mutation controls:

  • Y133F mutant alpha-synuclein (where tyrosine is replaced with phenylalanine)

  • Similar validation approaches show: "Specificity of the antibody was supported by lack of immunoreactivity following substituting Tyr125 to phenylalanine"

• Alpha-synuclein knockout samples:

  • Essential for identifying non-specific binding

  • Studies show antibodies often "detected non-specific low and high molecular weight bands in aSyn knock-out samples that could be easily mistaken for monomeric or high molecular weight aSyn species"

• Recombinant protein standards:

  • Purified recombinant alpha-synuclein with and without in vitro phosphorylation

  • Provides positive controls with known phosphorylation status

• Kinase manipulation controls:

  • Samples with increased phosphorylation through kinase overexpression

  • "Overexpression of shark increased phosphorylation at Tyr125 on α-syn WT"

• Neighboring PTM considerations:

  • Controls with different combinations of post-translational modifications

  • "Co-occurrence of multiple pathology-associated C-terminal post-translational modifications... differentially influences the detection"

• Technical assay controls:

  • For ELISA applications, include:

    • Anti-GAPDH Antibody as internal positive control

    • Crystal Violet whole-cell staining for cell normalization

    • Anti-alpha Synuclein Antibody for total protein normalization

Implementing these comprehensive controls ensures experimental rigor and enhances result reliability when working with Phospho-SNCA (Tyr133) antibodies.

How should researchers optimize experimental protocols for Phospho-SNCA (Tyr133) detection?

Optimizing experimental protocols for Phospho-SNCA (Tyr133) detection requires attention to several critical factors:

• Sample preparation and preservation:

  • Include phosphatase inhibitors immediately during sample collection

  • Process tissues rapidly to prevent post-mortem dephosphorylation

  • Studies show "reactivity of α-synuclein to anti-PY125 decreased with increasing intervals of incubation"

• Antibody selection and validation:

  • Choose antibodies specifically validated for Tyr133 phosphorylation

  • Verify specificity through multiple validation methods

  • Consider antibodies reported as "insensitive to neighboring PTMs"

• Application-specific optimizations:

  Western Blotting:

  • Recommended dilution ranges: 1:500-1:2000

  • Include proper molecular weight markers (alpha-synuclein ~14.5 kDa)

  • Use appropriate blocking agents (typically PBS with 0.05% Proclin300, 50% Glycerol, pH 7.3)

  ELISA Applications:

  • Starting antibody concentration: 1 μg/mL

  • Dynamic range: >5000 cells

  • Multiple normalization methods for cell-based assays

  Immunohistochemistry/Immunofluorescence:

  • Typical dilution range: 1:50-200 for IF, 1:100-1:300 for IHC

  • Optimize fixation protocols to preserve phosphorylation status

• Controls and standardization:

  • Include all necessary controls (see question 4.1)

  • Use consistent experimental conditions across samples

  • Implement appropriate normalization strategies

• Species considerations:

  • Most antibodies show reactivity to human, mouse, and rat alpha-synuclein

  • Verify cross-reactivity when working with other species

• Storage and handling:

  • Store antibodies at -20°C for up to 1 year

  • Avoid repeated freeze-thaw cycles

  • Use aliquots to minimize degradation

• Documentation of protocol parameters:

  • Record exact conditions, including buffer compositions

  • Document incubation times and temperatures

  • Note any deviations from manufacturer recommendations

These optimizations enhance detection sensitivity and specificity, improving experimental reliability when studying Phospho-SNCA (Tyr133).